Literature DB >> 2306518

Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms.

C W Taylor1, T M Grogan, S E Salmon.   

Abstract

Recombinant human interleukin-4 (rhIL-4) has pleiotropic biologic effects including stimulation of normal B-cell growth. We investigated the effects of rhIL-4 on the in vitro growth of 35 fresh human lymphoid and plasma cell malignancies. Inhibition of growth was seen in 52% and 60% of multiple myeloma and lymphoma specimens, respectively. Growth was stimulated relative to control in 8.6% (3 of 35) of the tumors tested. Immunophenotyping showed that tumors displaying growth stimulation expressed surface markers associated with a poor clinical prognosis. Our findings support the clinical evaluation of rhIL-4 as a therapeutic agent in selected patients with lymphoid and plasma cell neoplasms.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2306518

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  15 in total

1.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  M17, a gene specific for germinal center (GC) B cells and a prognostic marker for GC B-cell lymphomas, is dispensable for the GC reaction in mice.

Authors:  Dominik Schenten; Angela Egert; Manolis Pasparakis; Klaus Rajewsky
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

3.  Secretory IgA in saliva can be a useful stress marker.

Authors:  S Tsujita; K Morimoto
Journal:  Environ Health Prev Med       Date:  1999-04       Impact factor: 3.674

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapy.

Authors:  Kristopher A Sarosiek; Hovav Nechushtan; Xiaoqing Lu; Joseph D Rosenblatt; Izidore S Lossos
Journal:  Br J Haematol       Date:  2009-08-19       Impact factor: 6.998

Review 6.  Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.

Authors:  G Tosato; J Teruya-Feldstein; J Setsuda; S E Pike; K D Jones; E S Jaffe
Journal:  Springer Semin Immunopathol       Date:  1998

7.  IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

Authors:  Katherine R Calvo; Bhavana Dabir; Alexandra Kovach; Christopher Devor; Russell Bandle; Amelia Bond; Joanna H Shih; Elaine S Jaffe
Journal:  Blood       Date:  2008-08-05       Impact factor: 22.113

8.  Lack of effects of recombinant human interleukin-4 on in vitro colony formation of freshly explanted human tumor cells.

Authors:  A R Hanauske; D Degen; M H Marshall; P P Trotta; D D Von Hoff
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

9.  Interleukin-4 induces senescence in human renal carcinoma cell lines through STAT6 and p38 MAPK.

Authors:  Hag Dong Kim; Su-Jin Yu; Hee Suk Kim; Yong-Jin Kim; Jeong Min Choe; Yun Gyu Park; Joon Kim; Jeongwon Sohn
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

10.  Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.

Authors:  N I Obiri; G G Hillman; G P Haas; S Sud; R K Puri
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.